The Use of Targeted Agents in the Treatment of Gynecologic Cancers

Shaina F. Bruce, Matthew A. Powell

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Patients with advanced and recurrent ovarian, uterine, and cervical cancers have limited efficacious treatment options and poor outcomes. The development of agents that target DNA repair mechanisms, angiogenesis, immune checkpoints, and hormone receptor expression provides additional options for these patients. Many available targeted therapies have limited efficacy as single agents, so clinical trials investigating combination therapies as well as continued identification and validation of predictive biomarkers are critical. Many novel small molecule therapies, antibody drug conjugates, and therapeutic vaccines are also in development. This review will focus on recent evidence supporting the use of clinically available targeted therapies for gynecologic cancer.

Original languageEnglish
Pages (from-to)15-28
Number of pages14
JournalCurrent treatment options in oncology
Volume23
Issue number1
DOIs
StatePublished - Jan 2022

Keywords

  • Anti-angiogenics
  • Gynecologic cancer
  • Hormonal therapy
  • Immunotherapy
  • PARP inhibitor
  • Targeted therapy

Fingerprint

Dive into the research topics of 'The Use of Targeted Agents in the Treatment of Gynecologic Cancers'. Together they form a unique fingerprint.

Cite this